Pharma Newsletter – October 02 to October 06, 2017

India Infoline News Service | Mumbai | October 07, 2017 10:21 IST

This week, “Granules India informed that the USFDA has issued Establishment Inspection Report (EIR) for the Granules OmniChem facility, a 50:50 JV between the company and Ajinimoto OmniChem N.V. at Vizag, Andhra Pradesh.”

Top News
 
USFDA issues EIR for Granules India’s Vizag unit

Granules India informed that the USFDA has issued Establishment Inspection Report (EIR) for the Granules OmniChem facility, a 50:50 JV between the company and Ajinimoto OmniChem N.V. at Vizag, Andhra Pradesh. Read more
 
Natco Pharma’s partner Mylan launches generic Glatiramer Acetate in US market

Pharma major, Natco Pharma announced that its marketing partner Mylan N.V., has launched Glatiramer Acetate Injection 40 mg/ml as well as Glatiramer Acetate Injection 20 mg/ml in the US market. Read more
 
Cadila Healthcare receives USFDA nod for Fesoterodine Fumarate tablet

The share of Cadila Healthcare advanced by over 1% during Thursday’s trading session after the company informed that it has received the final approval from the USFDA to market Fesoterodine Fumarate extended-release tablets, 4 mg and 8 mg. Read more

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.